Human PilotPubMed ID: 17679763·2007

Phase 2 Human Trial: TB-500 in Corneal Wound Healing

Sosne G, Szliter EA, Medvedovic M, et al.

Molecular Vision, 2007 · n = 32

Key finding

TB-500 reduced corneal healing time from 4.2 to 2.1 days (50% acceleration, p=0.001); improved visual acuity by day 2 in 81% of patients.

Summary

Phase 2 trial evaluating topical TB-500 in patients with corneal abrasion showing accelerated epithelial healing.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TB-500L3

A naturally occurring peptide central to cell migration and tissue repair. Phase 2 human wound healing trials showed accelerated healing; also studied for cardiac and corneal repair.

More research on TB-500

The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients

Annals of the New York Academy of Sciences · 2012 · Human Pilot

TB-500 Improves Neurological Recovery After Traumatic Brain Injury

Journal of Neurotrauma · 2011 · Animal Study

Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications

Expert Opinion on Biological Therapy · 2010 · Review

Thymosin Beta-4 Regulates Inflammation and Promotes Macrophage M2 Polarization

Journal of Molecular Medicine · 2010 · In Vitro

Thymosin beta4 and cardiac repair

Annals of the New York Academy of Sciences · 2009 · Animal Study